E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1371-1379

  Visvanathan, Sudha ^a   Wagner, Carrie ^a   Rojas, Jeannie ^a   Kay, Jonathan ^b   Dasgupta, Bhaskar ^c   Matteson, Eric L ^d   Mack, Michael ^a   Baker, Daniel G ^a   Rahman, Mahboob U ^a,e  

^a CENTOCOR INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^d Mayo Clinic   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarkers; Bone turnover; Golimumab; Inflammation; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; GOLIMUMAB; INTERLEUKIN 18; METHOTREXATE; SERUM AMYLOID A; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; E-SELECTIN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-18; MALE; MATRIX METALLOPROTEINASE 9; METHOTREXATE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67650459136     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080755     Document Type: Article

References (20)

1. Feldmann M, Brennan FM, Maini RM. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:31-45.
3. Joosten LAB, Radstake TRD, Lubberts E, et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1β and tumor necrosis factor α in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003;48:339-47.
4. Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kB-dependent signal transduction pathway. Arthritis Rheum 2006;54:105-14.
5. Yildirim K, Senel K, Karatay S, et al. Serum E-selectin and erythrocyte membrane Na+K+ ATPase levels in patients with rheumatoid arthritis. Cell Biochem Funct 2005;23:285-9.
6. Cobankara V, Ozath D, Kiraz S, et al. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin Rheumatol 2004;23:430-4.
7. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391-6.
8. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
9. Pittoni V, Bombardieri M, Spinelli FR, et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002;61:723-5.
10. van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis 2005;64:537-43.
11. Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1088-93.
12. Visvanathan S, Marini JC, Smolen J, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007;34:1465-74.
13. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 2007;27:467-72.
14. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997;36:643-50.
15. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 2004;31:238-42.
16. Shealy D, Cai A, Lacy E, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFa. Ann Rheum Dis 2007;66 Suppl:151.
17. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
18. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998;54:1014-29.
19. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997;36:589-93.
20. Bosello S, Santoliquido A, Zoli A, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008;27:833-9.